The FDA's Center for Biologics Evaluation and Research (CBER) issued a Warning Letter to R3 Medical Companies on August 14, 2026 (Reference CBER 26-726330), following inspections conducted November 17–December 16, 2025, at facilities in Scottsdale, Arizona. The letter states that four umbilical cord-derived products (ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB) are unapproved new drugs in violation of FD&C Act section 505(a) and unlicensed biological products in violation of PHS Act section 351(a)(1), based on marketing claims across social media and websites indicating use for treating conditions including arthritis, diabetes, erectile dysfunction, autism, and organ failure. The letter also cites significant current good manufacturing practice (CGMP) violations under FD&C Act section 501(a)(2)(B) and 21 CFR parts 210 and 211, rendering the products adulterated.
live sample brief
This is what your daily brief looks like.
Not a mockup — the 3 most recent FDA Warning Letters Argus has actually ingested, summarized exactly the way they’d render in your 6am ET inbox: severity, citation, an AI summary, and a verbatim link back to fda.gov. If you subscribe today, letters matched to your watchlist look like this.
argus.hq — daily brief
3 recent FDA Warning Letters.
Live from Argus HQ’s own ingestion feed — not a demo.
FDA Center for Drug Evaluation and Research issued Warning Letter 320-26-114 on August 13, 2026, to Suretec Innovations, LLC (FEI 3030456591, Gilbert, Arizona) following a March 2-5, 2026 inspection. The letter cites CGMP violations under 21 CFR parts 210 and 211, including failure to test component identity and conformity to specifications, failure to validate supplier test reliability, and failure to list KleenLine Alcohol-Free Sanitizing Wipes in the FDA's eDRLS system, rendering the products adulterated and misbranded.
Eugia Pharma Specialities Limited — CGMP/Finished Pharmaceuticals/Adulterated (issued 2026-08-13)
On August 13, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Eugia Pharma Specialities Limited (FEI 3011960448, Hyderabad, India) citing significant Current Good Manufacturing Practice violations observed during a February 16-27, 2026 inspection of its sterile injectable drug manufacturing facility. The FDA documented inadequate aseptic processing design—including insufficient restricted access barrier system (RABS) elements, improper ISO 5 area separation, excessive uncontrolled operator interventions, and inadequate environmental monitoring—rendering finished drug products adulterated under the Federal Food, Drug, and Cosmetic Act. The agency found the company's March 20, 2026 response inadequate due to missing retrospective product impact assessment and unresolved RABS design flaws.
argus.hq
Get this matched to your watchlist, every weekday at 6am ET.
Set the companies, competitors, and CDMOs you track once — Argus reads every FDA Warning Letter the day it publishes and lands the ones that matter in your inbox. Plans from $99/month, cancel any time, 30-day money-back guarantee.
Argus HQ is informational only. Summaries above are AI-generated (Anthropic Claude) and may contain errors, misclassifications, or omissions. Always verify against the fda.gov source link before regulatory decisions. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.